1. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals
- Author
-
Andrabi, Raiees, Williams, Constance, Wang, Xiao-Hong, Li, Liuzhe, Choudhary, Alok K., Wig, Naveet, Biswas, Ashutosh, Luthra, Kalpana, Nadas, Arthur, Seaman, Michael S., Nyambi, Phillipe, Zolla-Pazner, Susan, and Gorny, Miroslaw K.
- Subjects
- *
MONOCLONAL antibodies , *HIV infections , *VIRAL vaccines , *GENETIC mutation , *VIRAL proteins , *BIOCHEMICAL templates - Abstract
Abstract: One approach to the development of an HIV vaccine is to design a protein template which can present gp120 epitopes inducing cross-neutralizing antibodies. To select a V3 sequence for immunogen design, we compared the neutralizing activities of 18 anti-V3 monoclonal antibodies (mAbs) derived from Cameroonian and Indian individuals infected with clade AG and C, respectively. It was found that V3 mAbs from the Cameroonian patients were significantly more cross-neutralizing than those from India. Interestingly, superior neutralizing activity of Cameroonian mAbs was also observed among the nine VH5-51/VL lambda genes encoding V3 mAbs which mediate a similar mode of recognition. This correlated with higher relative binding affinity to a variety of gp120s and increased mutation rates in V3 mAbs from Cameroon. These results suggest that clade C V3 is probably weakly immunogenic and that the V3 sequence of CRF02_AG viruses can serve as a plausible template for vaccine immunogen design. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF